- •Preface to the First Edition
- •Preface to the Second Edition
- •Contents
- •Diagnostic Challenges
- •Expert Centers
- •Patient Organizations
- •Clinical Trials
- •Research in Orphan Lung Diseases
- •Orphan Drugs
- •Orphanet
- •Empowerment of Patients
- •Conclusions
- •References
- •Introduction
- •Challenges to Overcome in Order to Undertake Quality Clinical Research
- •Lack of Reliable Data on Prevalence
- •Small Number of Patients
- •Identifying Causation/Disease Pathogenesis
- •Disease Complexity
- •Lack of Access to a Correct Diagnosis
- •Delay in Diagnosis
- •Challenges But Not Negativity
- •Some Success Stories
- •The Means to Overcome the Challenges of Clinical Research: Get Bigger Numbers of Well-Characterized Patients
- •The Importance of Patient Organizations
- •National and International Networks
- •End Points for Trials: Getting Them Right When Numbers Are Small and Change Is Modest
- •Orphan Drug Development
- •Importance of Referral Centers
- •Looking at the Future
- •The Arguments for Progress
- •Concluding Remarks
- •References
- •3: Chronic Bronchiolitis in Adults
- •Introduction
- •Cellular Bronchiolitis
- •Follicular Bronchiolitis
- •Respiratory Bronchiolitis
- •Airway-Centered Interstitial Fibrosis
- •Proliferative Bronchiolitis
- •Diagnosis
- •Chest Imaging Studies
- •Pulmonary Function Testing
- •Lung Biopsy
- •Mineral Dusts
- •Organic Dusts
- •Volatile Flavoring Agents
- •Infectious Causes of Bronchiolitis
- •Idiopathic Forms of Bronchiolitis
- •Connective Tissue Diseases
- •Organ Transplantation
- •Hematopoietic Stem Cell Transplantation
- •Drug-Induced Bronchiolitis
- •Treatment
- •Constrictive Bronchiolitis
- •Follicular Bronchiolitis
- •Airway-Centered Interstitial Fibrosis
- •Proliferative Bronchiolitis
- •References
- •Background and Epidemiology
- •Pathophysiology
- •Host Characteristics
- •Clinical Manifestations
- •Symptoms
- •Laboratory Evaluation
- •Skin Testing
- •Serum Precipitins
- •Eosinophil Count
- •Total Serum Immunoglobulin E Levels
- •Recombinant Antigens
- •Radiographic Imaging
- •Pulmonary Function Testing
- •Histology
- •Diagnostic Criteria
- •Historical Diagnostic Criteria
- •Rosenberg and Patterson Diagnostic Criteria
- •ISHAM Diagnostic Criteria
- •Cystic Fibrosis Foundation Diagnostic Criteria
- •General Diagnostic Recommendations
- •Allergic Aspergillus Sinusitis (AAS)
- •Natural History
- •Treatment
- •Corticosteroids
- •Antifungal Therapy
- •Monoclonal Antibodies
- •Monitoring for Treatment Response
- •Conclusions
- •References
- •5: Orphan Tracheopathies
- •Introduction
- •Anatomical Considerations
- •Clinical Presentation
- •Etiological Considerations
- •Idiopathic Subglottic Stenosis
- •Introduction
- •Clinical Features
- •Pulmonary Function Studies
- •Imaging Studies
- •Bronchoscopy
- •Treatment
- •Introduction and Clinical Presentation
- •Clinical Features
- •Pulmonary Function Studies
- •Imaging Studies
- •Bronchoscopy
- •Treatment
- •Tracheomalacia
- •Introduction
- •Clinical Features
- •Pulmonary Function Studies
- •Imaging Studies
- •Bronchoscopy
- •Treatment
- •Tracheobronchomegaly
- •Introduction
- •Clinical Features
- •Pathophysiology
- •Pulmonary Function Studies
- •Imaging Studies
- •Treatment
- •Tracheopathies Associated with Systemic Diseases
- •Relapsing Polychondritis
- •Introduction
- •Clinical Features
- •Laboratory Findings
- •Pulmonary Function and Imaging Studies
- •Treatment
- •Introduction
- •Clinical Features
- •Pulmonary Function Studies
- •Imaging Studies
- •Bronchoscopy
- •Treatment
- •Tracheobronchial Amyloidosis
- •Introduction
- •Clinical Features
- •Pulmonary Function Studies
- •Imaging Studies
- •Bronchoscopy
- •Treatment
- •Sarcoidosis
- •Introduction
- •Pulmonary Function Studies
- •Imaging Studies
- •Bronchoscopy
- •Treatment
- •Orphan Tracheopathies: Conclusions
- •References
- •6: Amyloidosis and the Lungs and Airways
- •Introduction
- •Diagnosis and Evaluation of Amyloidosis
- •Systemic AA Amyloidosis
- •Systemic AL Amyloidosis
- •Amyloidosis Localised to the Respiratory Tract
- •Laryngeal Amyloidosis
- •Tracheobronchial Amyloidosis
- •Parenchymal Pulmonary Amyloidosis
- •Pulmonary Amyloidosis Associated with Sjögren’s Disease
- •Conclusions
- •References
- •Introduction
- •Pathophysiology
- •Genetic Predisposition
- •Immune Dysregulation
- •Epidemiology
- •Incidence and Prevalence
- •Triggering Factors
- •Clinical Manifestations
- •General Symptoms
- •Pulmonary Manifestations
- •Ear, Nose, and Throat (ENT) Manifestations
- •Neurological Manifestations
- •Skin Manifestations
- •Cardiac Manifestations
- •Gastrointestinal Involvement
- •Renal Manifestations
- •Ophthalmological Manifestations
- •Complementary Investigations
- •Diagnosis
- •Diagnostic Criteria
- •Prognosis and Outcomes
- •Phenotypes According to the ANCA Status
- •Treatment
- •Therapeutic Strategies
- •Remission Induction
- •Maintenance Therapy
- •Other Treatments
- •Prevention of AEs
- •Conclusions
- •References
- •8: Granulomatosis with Polyangiitis
- •A Brief Historical Overview
- •Epidemiology
- •Pathogenesis
- •Clinical Manifestations
- •Constitutional Symptoms
- •Ear, Nose, and Throat (ENT) Manifestations
- •Pulmonary Manifestations
- •Kidney and Urological Manifestations
- •Kidney Manifestations
- •Urological Manifestations
- •Neurological Manifestations
- •Peripheral Nervous System (PNS) Manifestations
- •Central Nervous System (CNS) Manifestations
- •Spinal Cord and Cranial Nerve Involvement
- •Skin and Oral Mucosal Manifestations
- •Eye Manifestations
- •Cardiac Involvement
- •Gastrointestinal Manifestations
- •Gynecological and Obstetric Manifestations
- •Venous Thrombosis and Other Vascular Events
- •Other Manifestations
- •Pediatric GPA
- •Diagnosis
- •Diagnostic Approach
- •Laboratory Investigations
- •Biology
- •Immunology
- •Pathology
- •Treatment
- •Glucocorticoids
- •Cyclophosphamide
- •Rituximab
- •Other Current Induction Approaches
- •Other Treatments in GPA
- •Intravenous Immunoglobulins
- •Plasma Exchange
- •CTLA4-Ig (Abatacept)
- •Cotrimoxazole
- •Other Agents
- •Principles of Treatment for Relapsing and Refractory GPA
- •Outcomes and Prognostic Factors
- •Survival and Causes of Deaths
- •Relapse
- •Damage and Disease Burden on Quality of Life
- •Conclusions
- •References
- •9: Alveolar Hemorrhage
- •Introduction
- •Clinical Presentation
- •Diagnosis (Table 9.1, Fig. 9.3)
- •Pulmonary Capillaritis
- •Histology (Fig. 9.4)
- •Etiologies
- •ANCA-Associated Small Vessel Vasculitis: Granulomatosis with Polyangiitis (GPA)
- •ANCA-Associated Small Vessel Vasculitis: Microscopic Polyangiitis
- •Isolated Pulmonary Capillaritis
- •Systemic Lupus Erythematosus
- •Antiphospholipid Antibody Syndrome
- •Anti-Basement Membrane Antibody Disease (Goodpasture Syndrome)
- •Lung Allograft Rejection
- •Others
- •Bland Pulmonary Hemorrhage (Fig. 9.5)
- •Histology
- •Etiologies
- •Idiopathic Pulmonary Hemosiderosis
- •Drugs and Medications
- •Coagulopathy
- •Valvular Heart Disease and Left Ventricular Dysfunction
- •Other
- •Histology
- •Etiologies
- •Hematopoietic Stem Cell Transplantation (HSCT)
- •Cocaine Inhalation
- •Acute Exacerbation of Interstitial Lung Disease
- •Acute Interstitial Pneumonia
- •Acute Respiratory Distress Syndrome
- •Miscellaneous Causes
- •Etiologies
- •Pulmonary Capillary Hemangiomatosis
- •Treatment
- •Conclusions
- •References
- •Takayasu Arteritis
- •Epidemiology
- •Pathologic Features
- •Pathogenesis
- •Clinical Features
- •Laboratory Findings
- •Imaging Studies
- •Therapeutic Management
- •Prognosis
- •Behçet’s Disease
- •Epidemiology
- •Pathologic Features
- •Pathogenesis
- •Diagnostic Criteria
- •Clinical Features
- •Pulmonary Artery Aneurysm
- •Pulmonary Artery Thrombosis
- •Pulmonary Parenchymal Involvement
- •Laboratory Findings
- •Imaging Studies
- •Therapeutic Management
- •Treatment of PAA
- •Treatment of PAT
- •Prognosis
- •References
- •Introduction
- •Portopulmonary Hypertension (PoPH)
- •Epidemiology and Risk Factors
- •Molecular Pathogenesis
- •PoPH Treatment
- •Hepatopulmonary Syndrome (HPS)
- •Epidemiology and Risk Factors
- •Molecular Pathogenesis
- •HPS Treatment
- •Conclusion
- •References
- •12: Systemic Sclerosis and the Lung
- •Introduction
- •Risk factors for SSc-ILD
- •Genetic Associations
- •Clinical Presentation of SSc-ILD
- •Pulmonary Function Tests (PFTs)
- •Imaging
- •Management
- •References
- •13: Rheumatoid Arthritis and the Lungs
- •Introduction
- •Epidemiology
- •Risk Factors for ILD (Table 13.3)
- •Pathogenesis
- •Clinical Features and Diagnosis
- •Treatments
- •Prognosis
- •Epidemiology
- •Risk Factors
- •Clinical Features, Diagnosis, and Outcome
- •Subtypes or RA-AD
- •Obliterative Bronchiolitis
- •Bronchiectasis
- •COPD
- •Cricoarytenoid Involvement
- •Pleural Disease
- •Conclusion
- •References
- •Introduction
- •Systemic Lupus Erythematosus
- •Epidemiology
- •Pathophysiology
- •Pulmonary Manifestations
- •Pleural Disease
- •Shrinking Lung Syndrome
- •Thrombotic Manifestations
- •Interstitial Lung Disease
- •Other Pulmonary Manifestations
- •Prognosis
- •Sjögren’s Syndrome
- •Epidemiology
- •Pathophysiology
- •Pulmonary Manifestations
- •Airway Disorders
- •Lymphoproliferative Disease
- •Interstitial Lung Disease
- •Prognosis
- •Mixed Connective Tissue Disease
- •Epidemiology
- •Pathophysiology
- •Pulmonary Manifestations
- •Pulmonary Hypertension
- •Interstitial Lung Disease
- •Prognosis
- •Myositis
- •Epidemiology
- •Pathophysiology
- •Pulmonary Manifestations and Treatments
- •Interstitial Lung Disease
- •Respiratory Muscle Weakness
- •Other Pulmonary Manifestations
- •Prognosis
- •Other Therapeutic Options in CTD-ILD
- •Lung Transplantation
- •Conclusion
- •References
- •Introduction
- •Diagnostic Criteria
- •Controversies in the Diagnostic Criteria
- •Typical Clinical Features
- •Disease Progression and Prognosis
- •Summary
- •References
- •Introduction
- •Histiocytes and Dendritic Cells
- •Introduction
- •Cellular and Molecular Pathogenesis
- •Pathology
- •Clinical Presentation
- •Treatment and Prognosis
- •Erdheim-Chester Disease
- •Epidemiology
- •Cellular and Molecular Pathogenesis
- •Histopathology and Immunohistochemistry
- •Clinical Presentation
- •Investigation/Diagnosis
- •Chest Studies
- •Cardiovascular Imaging
- •CNS Imaging
- •Bone Radiography
- •Other Imaging Findings and Considerations
- •Disease Monitoring
- •Pathology
- •Management/Treatment
- •Prognosis
- •Rosai-Dorfman Destombes Disease
- •Epidemiology
- •Etiology/Pathophysiology
- •Histopathology and Immunohistochemistry
- •Clinical Presentation
- •Investigation/Diagnosis
- •Management/Treatment
- •Prognosis
- •Conclusions
- •Diagnostic Criteria for Primary Histiocytic Disorders of the Lung
- •References
- •17: Eosinophilic Pneumonia
- •Introduction
- •Eosinophil Biology
- •Physiologic and Immunologic Role of Eosinophils
- •Release of Mediators
- •Targeting the Eosinophil Cell Lineage
- •Historical Perspective
- •Clinical Presentation
- •Pathology
- •Diagnosis
- •Eosinophilic Lung Disease of Undetermined Cause
- •Idiopathic Chronic Eosinophilic Pneumonia
- •Clinical Features
- •Imaging
- •Laboratory Studies
- •Bronchoalveolar Lavage
- •Lung Function Tests
- •Treatment
- •Outcome and Perspectives
- •Clinical Features
- •Imaging
- •Laboratory Studies
- •Bronchoalveolar Lavage
- •Lung Function Tests
- •Lung Biopsy
- •Treatment and Prognosis
- •Eosinophilic Granulomatosis with Polyangiitis
- •History and Nomenclature
- •Pathology
- •Clinical Features
- •Imaging
- •Laboratory Studies
- •Pathogenesis
- •Diagnosis
- •Treatment and Prognosis
- •Long-Term Outcome
- •Hypereosinophilic Syndrome
- •Pathogenesis
- •Clinical and Imaging Features
- •Laboratory Studies
- •Treatment and Prognosis
- •Eosinophilic Pneumonias of Parasitic Origin
- •Tropical Eosinophilia [191]
- •Ascaris Pneumonia
- •Eosinophilic Pneumonia in Larva Migrans Syndrome
- •Strongyloides Stercoralis Infection
- •Eosinophilic Pneumonias in Other Infections
- •Allergic Bronchopulmonary Aspergillosis
- •Pathogenesis
- •Diagnostic Criteria
- •Biology
- •Imaging
- •Treatment
- •Bronchocentric Granulomatosis
- •Miscellaneous Lung Diseases with Associated Eosinophilia
- •References
- •Introduction
- •Pulmonary Langerhans’ Cell Histiocytosis
- •Epidemiology
- •Pathogenesis
- •Diagnosis
- •Clinical Features
- •Extrathoracic Lesions
- •Pulmonary Function Tests
- •Chest Radiography
- •High-Resolution Computed Tomography (HRCT)
- •Bronchoscopy and Bronchoalveolar Lavage (BAL)
- •Lung Biopsy
- •Pathology
- •Treatment
- •Course and Prognosis
- •Case Report I
- •Introduction
- •Epidemiology
- •Clinical Features
- •Histopathological Findings
- •Radiologic Findings
- •Prognosis and Therapy
- •Desquamative Interstitial Pneumonia
- •Epidemiologic and Clinical Features
- •Histopathological Findings
- •Radiological Findings
- •Prognosis and Therapy
- •Conclusion
- •References
- •19: Lymphangioleiomyomatosis
- •Introduction
- •Pathogenesis
- •Presentation
- •Prognosis
- •Management
- •General Measures
- •Parenchymal Lung Disease
- •Pleural Disease
- •Renal Angiomyolipoma
- •Abdominopelvic Lymphatic Disease
- •Pregnancy
- •Tuberous Sclerosis
- •Drug Treatment
- •Bronchodilators
- •mTOR Inhibitors
- •Anti-Oestrogen Therapy
- •Experimental Therapies
- •Interventions for Advanced Disease
- •Oxygen Therapy
- •Pulmonary Hypertension
- •References
- •20: Diffuse Cystic Lung Disease
- •Introduction
- •Lymphangioleiomyomatosis
- •Pathogenesis
- •Pathologic and Radiographic Characteristics
- •Diagnostic Approach
- •Pulmonary Langerhans Cell Histiocytosis (PLCH)
- •Pathogenesis
- •Pathological and Radiographic Characteristics
- •Diagnostic Approach
- •Birt-Hogg-Dubé Syndrome (BHD)
- •Pathogenesis
- •Pathological and Radiographic Characteristics
- •Diagnostic Approach
- •Lymphoproliferative Disorders
- •Pathogenesis
- •Pathological and Radiographic Characteristics
- •Diagnostic Approach
- •Amyloidosis
- •Light Chain Deposition Disease (LCDD)
- •Conclusion
- •References
- •Introduction
- •Lymphatic Development
- •Clinical Presentation of Lymphatic Disorders
- •Approaches to Diagnosis and Management of Congenital Lymphatic Anomalies
- •Generalized Lymphatic Anomaly
- •Etiopathogenesis
- •Clinical Presentation and Diagnosis
- •Course/Prognosis
- •Management
- •Kaposiform Lymphangiomatosis
- •Etiopathogenesis
- •Clinical Presentation and Diagnosis
- •Management
- •Course/Prognosis
- •Gorham Stout Disease
- •Etiopathogenesis
- •Clinical Presentation and Diagnosis
- •Management
- •Course/Prognosis
- •Channel-Type LM/Central Conducting LM
- •Etiopathogenesis
- •Clinical Presentation and Diagnosis
- •Management
- •Course/Prognosis
- •Yellow Nail Syndrome
- •Etiopathogenesis
- •Clinical Presentation and Diagnosis
- •Management
- •Course/Prognosis
- •Summary
- •References
- •Introduction
- •Historical Note
- •Epidemiology
- •Pathogenesis
- •Surfactant Homeostasis in PAP
- •GM-CSF Signaling Disruption
- •Myeloid Cell Dysfunction
- •GM-CSF Autoantibodies
- •Lymphocytosis
- •Clinical Manifestations
- •Clinical Presentation
- •Secondary Infections
- •Pulmonary Fibrosis
- •Diagnosis
- •Pulmonary Function Testing
- •Radiographic Assessment
- •Bronchoscopy and Bronchoalveolar Lavage
- •Laboratory Studies and Biomarkers
- •GM-CSF Autoantibodies
- •Genetic Testing
- •Lung Pathology
- •Diagnostic Approach to the Patient with PAP
- •Natural History and Prognosis
- •Treatment
- •Whole-Lung Lavage
- •Subcutaneous GM-CSF
- •Inhaled GM-CSF
- •Other Approaches
- •Conclusions and Future Directions
- •References
- •Introduction
- •Epidemiology
- •Gastric Contents
- •Pathobiology of GER/Microaspirate in the Lungs of Patients with IPF
- •GER and the Microbiome
- •Diagnosis
- •Clinical History/Physical Exam
- •Investigations
- •Esophageal Physiology
- •Upper Esophageal Sphincter
- •Esophagus and Peristalsis
- •Lower Esophageal Sphincter and Diaphragm
- •Esophageal pH and Impedance Testing
- •High Resolution Esophageal Manometry
- •Esophagram/Barium Swallow
- •Bronchoalveolar Lavage/Sputum: Biomarkers
- •Treatment
- •Anti-Acid Therapy (PPI/H2 Blocker)
- •GER and Acute Exacerbations of IPF
- •Suggested Approach
- •Summary and Future Directions
- •References
- •Introduction
- •Familial Interstitial Pneumonia
- •Telomere Related Genes
- •Genetic
- •Telomere Length
- •Pulmonary Involvement
- •Interstitial Lung Disease
- •Other Lung Disease
- •Hepatopulmonary Syndrome
- •Emphysema
- •Extrapulmonary Manifestations
- •Mucocutaneous Involvement
- •Hematological Involvement
- •Liver Involvement
- •Other Manifestations
- •Treatment
- •Telomerase Complex Agonists
- •Lung Transplantation
- •Surfactant Pathway
- •Surfactant Protein Genes
- •Pulmonary Involvement
- •Treatment
- •Heritable Forms of Pulmonary Fibrosis with Autoimmune Features
- •TMEM173
- •COPA
- •Pulmonary Alveolar Proteinosis
- •GMCSF Receptor Mutations
- •GATA2
- •MARS
- •Lysinuric Protein Intolerance
- •Lysosomal Diseases
- •Hermansky-Pudlak Syndrome
- •Lysosomal Storage Disorders
- •FAM111B, NDUFAF6, PEPD
- •Conclusion
- •References
- •Introduction
- •Pathophysiology
- •Clinical Presentation
- •Epidemiology
- •Genetic Causes of Bronchiectasis
- •Disorders of Mucociliary Clearance
- •Cystic Fibrosis
- •Primary Ciliary Dyskinesia
- •Other Ciliopathies
- •X-Linked Agammaglobulinemia
- •Chronic Granulomatous Disease and Other Disorders of Neutrophil Function
- •Other Genetic Disorders Predisposing to Bronchiectasis
- •Idiopathic Bronchiectasis
- •Diagnosis of Bronchiectasis
- •Management of Patients with Bronchiectasis
- •Airway Clearance Therapy (ACT)
- •Management of Infections
- •Immune Therapy
- •Surgery
- •Novel Therapies for Managing Cystic Fibrosis
- •Summary
- •References
- •Pulmonary Arteriovenous Malformations
- •Background Pulmonary AVMs
- •Anatomy Pulmonary AVMs
- •Clinical Presentation of Pulmonary AVMs
- •Screening Pulmonary AVMs
- •Treatment Pulmonary AVMs
- •Children with Hereditary Hemorrhagic Telangiectasia
- •Pulmonary Hypertension
- •Pulmonary Hypertension Secondary to Liver Vascular Malformations
- •Pulmonary Arterial Hypertension
- •Background HHT
- •Pathogenesis
- •References
- •27: Pulmonary Alveolar Microlithiasis
- •Introduction
- •Epidemiology
- •Pathogenesis
- •Clinical Features
- •Diagnosis
- •Management
- •Summary
- •References
- •Introduction
- •Hermansky-Pudlak Syndrome
- •Telomerase-Associated Pulmonary Fibrosis
- •Lysosomal Storage Diseases
- •Lysinuric Protein Intolerance
- •Familial Hypocalciuric Hypercalcemia
- •Surfactant Dysfunction Disorders
- •Concluding Remarks
- •References
- •Introduction
- •Background
- •Image Acquisition
- •Key Features of Fibrosis
- •Ancillary Features of Fibrosis
- •Other Imaging Findings in FLD
- •Probable UIP-IPF
- •Indeterminate
- •Alternative Diagnosis
- •UIP in Other Fibrosing Lung Diseases
- •Pleuroparenchymal Fibroelastosis (PPFE)
- •Combined Pulmonary Fibrosis and Emphysema
- •Chronic Hypersensitivity Pneumonitis
- •Other Fibrosing Lung Diseases
- •Fibrosing Sarcoidosis
- •CTD-ILD and Drug-Induced FLD
- •Complications
- •Prognosis
- •Computer Analysis of CT Imaging
- •The Progressive Fibrotic Phenotype
- •Other Imaging Techniques
- •Conclusion
- •References
- •Introduction
- •Bronchoalveolar Lavage (BAL)
- •Technique
- •Interpretation
- •Transbronchial Biopsy (TBB)
- •Transbronchial Lung Cryobiopsy (TLCB)
- •References
- •Introduction
- •Overview of ILD Diagnosis
- •Clinical Assessment
- •Radiological Assessment
- •Laboratory Assessment
- •Integration of Individual Features
- •Multidisciplinary Discussion
- •Diagnostic Ontology
- •Conclusions
- •References
- •Introduction
- •Idiopathic Pulmonary Fibrosis
- •Chronic Hypersensitivity Pneumonitis
- •Connective Tissue Disease
- •Drug-Induced Lung Diseases
- •Radiation Pneumonitis
- •Asbestosis
- •Hermansky-Pudlak Syndrome
- •Risk Factors for Progression
- •Diagnosis
- •Pharmacological Management
- •Conclusions
- •References
- •Historical Perspective
- •Epidemiology and Etiologies
- •Tobacco Smoking and Male Sex
- •Genetic Predisposition
- •Systemic Diseases
- •Other Etiological Contexts
- •Clinical Manifestations
- •Pulmonary Function and Physiology
- •Imaging
- •Computed Tomography Characteristics and Patterns
- •Thick-Walled Large Cysts
- •Imaging Phenotypes
- •Pitfalls
- •Pathology
- •Diagnosis
- •CPFE Is a Syndrome
- •Biology
- •Complications and Outcome
- •Mortality
- •Pulmonary Hypertension
- •Lung Cancer
- •Acute Exacerbation of Pulmonary Fibrosis
- •Other Comorbidities and Complications
- •Management
- •General Measures and Treatment of Emphysema
- •Treatment of Pulmonary Fibrosis
- •Management of Pulmonary Hypertension
- •References
- •Acute Interstitial Pneumonia (AIP)
- •Epidemiology
- •Presentation
- •Diagnostic Evaluation
- •Radiology
- •Histopathology
- •Clinical Course
- •Treatment
- •Epidemiology
- •Presentation
- •Diagnostic Evaluation
- •Radiology
- •Histopathology
- •Clinical Course
- •Desquamative Interstitial Pneumonia (DIP)
- •Presentation
- •Diagnostic Evaluation
- •Radiology
- •Histopathology
- •Clinical Course
- •Treatment
- •Epidemiology
- •Presentation
- •Diagnostic Evaluation
- •Radiology
- •Histopathology
- •Clinical Course
- •Treatment
- •References
- •Organizing Pneumonias
- •Epidemiology
- •Pathogenesis
- •Clinical Features
- •Imaging
- •Multifocal Form
- •Isolated Nodular Form
- •Other Imaging Patterns
- •Histopathological Diagnosis of OP Pattern
- •Etiological Diagnosis of OP
- •Treatment
- •Clinical Course and Outcome
- •Severe Forms of OP with Respiratory Failure
- •Acute Fibrinous and Organizing Pneumonia
- •Granulomatous Organizing Pneumonia
- •Acute Interstitial Pneumonia
- •Epidemiology
- •Clinical Picture
- •Imaging
- •Histopathology
- •Diagnosis
- •Treatment
- •Outcome
- •References
- •36: Pleuroparenchymal Fibroelastosis
- •Introduction
- •Epidemiology
- •Clinical Manifestations
- •Laboratory Findings
- •Respiratory Function
- •Radiologic Features
- •Pathologic Features
- •Diagnosis
- •Treatment
- •Prognosis
- •Conclusions
- •References
- •Introduction
- •Acute Berylliosis
- •Chronic Beryllium Disease
- •Exposure
- •Epidemiology
- •Immunopathogenesis and Pathology
- •Genetics
- •Clinical Description and Natural History
- •Treatment and Monitoring
- •Indium–Tin Oxide-Lung Disease
- •Hard Metal Lung
- •Flock Worker’s Disease
- •Asbestosis
- •Nanoparticle Induced ILD
- •Flavoring-Induced Lung Disease
- •Silica-Induced Interstitial Lung Disease
- •Chronic Silicosis
- •Acute and Accelerated Silicosis
- •Chronic Obstructive Disease in CMDLD
- •Simple CMDLD
- •Complicated CMDLD
- •Conclusion
- •References
- •38: Unclassifiable Interstitial Lung Disease
- •Introduction
- •Diagnostic Scenarios
- •Epidemiology
- •Clinical Presentation
- •Diagnosis
- •Clinical Features
- •Radiology
- •Laboratory Investigations
- •Pathology
- •Conclusion
- •References
- •39: Lymphoproliferative Lung Disorders
- •Introduction
- •Nodular Lymphoid Hyperplasia
- •Lymphocytic Interstitial Pneumonia (LIP)
- •Follicular Bronchitis/Bronchiolitis
- •Castleman Disease
- •Primary Pulmonary Lymphomas
- •Primary Pulmonary MALT B Cell Lymphoma
- •Pulmonary Plasmacytoma
- •Follicular Lymphoma
- •Lymphomatoid Granulomatosis
- •Primary Pulmonary Hodgkin Lymphoma (PPHL)
- •Treatment
- •References
- •Introduction
- •Late-Onset Pulmonary Complications
- •Bronchiolitis Obliterans (BO)
- •Pathophysiology
- •Diagnosis
- •Management of BOS
- •Post-HSCT Organizing Pneumonia
- •Other Late-Onset NonInfectious Pulmonary Complications (LONIPCs)
- •Conclusion
- •References
- •Introduction
- •Pulmonary Hypertension Associated with Sarcoidosis (Group 5.2)
- •PH Associated with Pulmonary Langerhans Cell Histiocytosis (Group 5.2)
- •PH in Combined Pulmonary Fibrosis and Emphysema (Group 3.3)
- •PH Associated with Lymphangioleiomyomatosis (Group 3)
- •Hereditary Hemorrhagic Telangiectasia (Group 1.2)
- •Pulmonary Veno-Occlusive Disease (Group 1.5)
- •Small Patella Syndrome (Group 1.2)
- •Conclusion
- •References
- •Introduction
- •Epidemiology
- •Timing, Chronology, Delay Time
- •Route of Administration
- •Patterns of Involvement [3, 4]
- •Drugs and Agents Fallen Out of Favor
- •Drug-Induced Noncardiac Pulmonary Edema
- •Drug-Induced Cardiogenic Pulmonary Edema
- •The “Chemotherapy Lung”
- •Drug-Induced/Iatrogenic Alveolar Hemorrhage
- •Drugs
- •Superwarfarin Rodenticides
- •Transfusion Reactions: TACO–TRALI
- •Acute Eosinophilic Pneumonia
- •Acute Granulomatous Interstitial Lung Disease
- •Acute Organizing Pneumonia (OP), Bronchiolitis Obliterans Organizing Pneumonia (BOOP), or Acute Fibrinous Organizing Pneumonia (AFOP) Patterns
- •Acute Amiodarone-Induced Pulmonary Toxicity (AIPT)
- •Accelerated Pulmonary Fibrosis
- •Acute Exacerbation of Previously Known (Idiopathic) Pulmonary Fibrosis
- •Anaphylaxis
- •Acute Vasculopathy
- •Drug-Induced/Iatrogenic Airway Emergencies
- •Airway Obstruction as a Manifestation of Anaphylaxis
- •Drug-Induced Angioedema
- •Hematoma Around the Upper Airway
- •The “Pill Aspiration Syndrome”
- •Catastrophic Drug-Induced Bronchospasm
- •Peri-operative Emergencies (Table 42.8)
- •Other Rare Presentations
- •Pulmonary Nodules and Masses
- •Pleuroparenchymal Fibroelastosis
- •Late Radiation-Induced Injury
- •Chest Pain
- •Rebound Phenomenon
- •Recall Pneumonitis
- •Thoracic Bezoars: Gossipybomas
- •Respiratory Diseases Considered Idiopathic That May Be Drug-Induced (Table 42.4)
- •Eye Catchers
- •Conclusion
- •References
- •Cancer Mimics of Organizing Pneumonia
- •Lung Adenocarcinoma/Bronchioloalveolar Carcinoma
- •Primary Pulmonary Lymphoma
- •Cancer Mimics of Interstitial Lung Diseases
- •Lymphangitic Carcinomatosis
- •Epithelioid Hemangio-Endothelioma
- •Lymphomatoid Granulomatosis
- •Cystic Tumors
- •Cavitating Tumors
- •Intrathoracic Pseudotumors
- •Respiratory Papillomatosis
- •Pulmonary Langerhans Cell Histiocytosis
- •References
- •Index
770 |
P. Bonniaud and P. Camus |
|
|
following administration of chemotherapy or ICI. Other examples include ARDS triggered by oxygen in patients previously exposed to amiodarone [127].
Thoracic Bezoars: Gossipybomas
Bezoars and pharmacobezoars are aggregates of food or other foreign material or drugs. They may localize in the chest, obstructing the central airway or esophagus (sometimes rendering the esophagus spontaneously visible on a chest radiograph).
Pharmacobezoars including body packing may act as a slow release drug reservoir capable of releasing the drug and “mysteriously” perpetuating the adverse effects despite apparent withdrawal of the drug [189].
Postoperative leftovers (surgical sponge, throat packs, surgical fabric or catheters) may lead to a foreign body retention named gossypibomas or textilomas [3, 4]. These have distinctive HRCT features [190] and can simulate chest malignancy [191, 192].
Respiratory Diseases Considered Idiopathic That May Be Drug-Induced (Table 42.4)
A number of common diseases commonly named as “idiopathic” including such ILD as cellular NSIP, organizing pneumonia, pulmonary alveolar proteinosis, pulmonarybrosis, exacerbated pulmonary brosis, sarcoidosis, ILD with a granulomatous component, hilar or mediastinal lymphadenopathy, pulmonary edema, ARDS, alveolar hemorrhage, angioedema, deterioration of asthma, chronic cough, pleural effusion including chylothorax, pulmonary embolism, emphysema, disordered breathing during sleep, hiccup, and such systemic syndromes as lupus, drug rash with eosinophilia and systemic symptoms, ANCA-related vasculitis, eosinophilic granulomatosis and polyangiitis, interstitial pneumonia with autoimmune features, myositis or polymyositis, the multiple organ dysfunction syndrome, or cardiomyopathy can all be triggered or caused by drugs [3, 4]. Consideration of the drug etiology can be rewarding in terms of reversal of all signs and symptoms with drug removal.
Eye Catchers
The reader is invited to visit the appropriate section of “eye- catching” images in pneumotox, where drug-induced and iatrogenic conditions may be so distinctive as to enable almost instant diagnosis [3, 4].
Conclusion
Drug-induced and iatrogenic respiratory problems are manifold and can be immediately life-threatening or fatal. Many are rare if not exceptional. Prevention rests on educating our-
selves and our colleagues and pupils in all specialties about the respiratory reactions that may occur with the drugs they prescribe, identifying risk factors, a high index of suspicion, examining any sign or symptom or constellation thereof for possible drug-relatedness using pneumotox and the literature [3, 4], avoidance of hazardous combination treatments, prompt identi cation of the causal agent and its removal, reliable measures to avoid inadvertent rechallenge with the culprit drug, and publication of cases. It is worth mentioning that household substances and chemicals can also cause eminently preventable acute lung or respiratory injury [3, 4]. For all causes and patterns of injury, Pneumotox can be accessed at any time through the appropriate website or App.
References
1.\Osler W. Oedema of the left lung - morphia poisoning. Montreal general hospital reports clinical and pathological, vol. 1. Montreal, QC: M Dawson Bros Publishers; 1880. p. 291–2.
2.\Sternbach G. William Osler: narcotic-induced pulmonary edema. J Emerg Med. 1983;1:165–7.
3.\Pneumotox. II (V2.2) Website: 2018. Producer: Ph Camus: Last update: April 19, 2022. 2018. https://www.pneumotox.com.
4.\Pneumotox. Pneumotox-App: Pneumotox II (V2.2-mobile) App: 2019. Producer: Ph Camus: Last update: April 18, 2022; 2019.
5.\Hill AB. The environment and disease: association or causation? Proc R Soc Med. 1965;58:295–300.
6.\Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–45.
7.\Felip E, Llobera L, Perez-Mañá C, Quintela D, Guasch I, Margelí M, Teruel I, Cirauqui B, Centeno C, Romeo M, Ballana E, Quiroga V. New drugs, old toxicities: pneumonitis related to palbociclib - a case report. Breast Care. 2020;15:548–52.
8.\Cardiotox. Cardiotox-App: Cardiotox (V1.0-mobile) App: 2021. Producer: Ph Camus: Last update: April 19, 2022; 2021.
9.\Miller JO, Shih AR, Mino-Kenudson M, Taylor MS, Goldman JL. Trimethoprim-sulfamethoxazole-associated fulminant respiratory failure in children and young adults. Am J Respir Crit Care Med. 2021;203:918–21.
10.\Sears CR, Peikert T, Possick JD, Naidoo J, Nishino M, Patel SP, Camus P, Gaga M, Garon EB, Gould MK, Limper AH, Montgrain PR, Travis WD, Rivera MP. Knowledge gaps and research priorities in immune checkpoint inhibitor-related pneumonitis. An Of cial American Thoracic Society Research Statement. Am J Respir Crit Care Med. 2019;200:e31–43.
11.\Spagnolo P, Bonniaud P, Rossi G, Sverzellati N, Cottin V. Drug- induced interstitial lung disease. Eur Respir J. 2022;
12.\Hayes D Jr, Board A, Calfee C, Ellington S, Pollack LA, Kathuria H, Eakin MN, Weissman DN, Callahan SJ, Esper AM, Crotty Alexander LE, Sharma NS, Meyer NJ, Smith LS, Novosad S, Evans ME, Goodman AB, Click ES, Robinson RT, Ewart G, et al. Pulmonary and critical care considerations for e-cigarette, or vaping, product use-associated lung injury (EVALI). Chest. 2022;162:256.
13.\Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infiximab therapy. Arthritis Rheum. 2004;50:372–9.
14.\Wakeman SE. Opioid use disorder diagnosis and management. N Engl J Med Evid. 2022;1:1.
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
42 Drug-Induced/Iatrogenic Respiratory Disease: With Emphasis on Unusual, Rare, and Emergent Drug-Induced Reactions |
771 |
|
|
15.\Vujaklija Brajković A, Grgat M, Bielen L, Brajković J, Zlopaša O, Vrdoljak NG, Radonić R. Self-poisoning as a cause of admission in a medical intensive care unit and a question of misuse of prescription medications. Heart Lung. 2021;51:17–21.
16.\Ciottone GR. Toxidrome recognition in chemical-weapons attacks. N Engl J Med. 2018;378:1611–20.
17.\Chai PR, Hayes BD, Erickson TB, Boyer EW. Novichok agents: a historical, current, and toxicological perspective. Toxicol Commun. 2018;2:45–8.
18.\Henretig FM, Kirk MA, McKay CA Jr. Hazardous chemical emergencies and poisonings. N Engl J Med. 2019;380:1638–55.
19.\Dart RC, Goldfrank LR, Erstad BL, Huang DT, Todd KH, Weitz J, Bebarta VS, Caravati EM, Henretig FM, Delbridge TR, Banner W, Schneider SM, Anderson VE. Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care. Ann Emerg Med. 2018;71:314–325.e1.
20.\Upadhyaya VD, Douedi S, Akula M, Chalasani KK, Saybolt MD, Hossain M. Amiodarone-induced thyroid storm causing sustained monomorphic ventricular tachycardia treated with plasmapheresis: a challenging clinical case. J Med Cases. 2020;11:79–81.
21.\Abrams JL, Fermi D, Belligund P, McFarlane SI. Amiodarone- induced hypothyroidism related to pericardial effusion with tamponade physiology. Cureus. 2022;14:e22932.
22.\André MC, Hammer J. Life-threatening accidental intravenous epinephrine overdose in a 12-year-old boy. Pediatr Emerg Care. 2018;35:e110–2.
23.\Haleem Z, Gradon JD. Radiographic Evolution of Presumed Septic Pulmonary Emboli. N Engl J Med. 2022;386:1452.
24.\Kummer RL, Kempainen RR, Olives TD, Leatherman JW, Prekker ME. Naloxone-associated pulmonary edema following recreational opioid overdose: a case series. Am J Emerg Med. 2021;53:41–3.
25.\Case B, Oszko MA. Use of an algorithm to evaluate published reports of adverse drug reactions. Am J Hosp Pharm. 1991;48:121–2.
26.\Naranjo CA, Lanctot KL. Recent developments in computer- assisted diagnosis of putative adverse drug reactions. Drug Saf. 1991;6:315–22.
27.\Koyama N, Iwase O, Nakashima E, Kishida K, Kondo T, Watanabe Y, Takahashi H, Umebayashi Y, Ogawa Y, Miura H. High incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature review. BMC Pulm Med. 2018;18:23.
28.\Pozzessere C, Bouchaab H, Jumeau R, Letovanec I, Daccord C, Bourhis J, Prior JO, Peters S, Lazor R, Beigelman-Aubry C. Relationship between pneumonitis induced by immune checkpoint inhibitors and the underlying parenchymal status: a retrospective study. ERJ Open Res. 2020;6:00165.
29.\Johkoh T, Lee KS, Nishino M, Travis WD, Ryu JH, Lee HY, Ryerson CJ, Franquet T, BankierAA, Brown KK, Goo JM, Kauczor HU, Lynch DA, Nicholson AG, Richeldi L, Schaefer-Prokop CM, Verschakelen J, Raoof S, Rubin GD, Powell C, et al. Chest CT diagnosis and clinical management of drug-related pneumonitis in patients receiving molecular targeting agents and immune checkpoint inhibitors: a position paper from the Fleischner Society. Radiology. 2021;298:550–66.
30.\Johkoh T, Lee KS, Nishino M, Travis WD, Ryu JH, Lee HY, Ryerson CJ, Franquet T, Bankier AA, Brown KK, Goo JM, Kauczor HU, Lynch DA, Nicholson AG, Richeldi L, Schaefer- Prokop CM, Verschakelen J, Raoof S, Rubin GD, Powell C, et al. Chest CT diagnosis and clinical management of drug-related pneumonitis in patients receiving molecular targeting agents and immune checkpoint inhibitors: a position paper from the Fleischner Society. Chest. 2021;159:1107–25.
31.\Cleverley JR, Screaton NJ, Hiorns MP, Flint JD, Müller NL. Drug- induced lung disease: high-resolution CT and histological ndings. Clin Radiol. 2002;57:292–9.
32.\Yoneda KY, Shelton DK, Beckett LA, Gandara DR. Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer. J Thorac Oncol. 2007;2:537–43.
33.\Hansell DM, Bankier AA, MacMahon H, McLoud TC, Müller NL, Rémy J. Fleischner Society: glossary of terms tor thoracic imaging. Radiology. 2008;246:697–722.
34.\Thomeer M, Demedts M, Vandeurzen K. Registration of interstitial lung diseases by 20 centres of respiratory medicine in Flanders. Acta Clin Belg. 2001;56:163–72.
35.\Dhokarh R, Li G, Schmickl CN, Kashyap R, Assudani J, Limper AH, Gajic O. Drug associated acute lung injury: a population based cohort study. Chest. 2012;142:845–50.
36.\Rabe C, Appenrodt B, Hoff C, Ewig S, Klehr HU, Sauerbruch T, Nickenig G, Tasci S. Severe respiratory failure due to diffuse alveolar hemorrhage: clinical characteristics and outcome of intensive care. J Crit Care. 2009;25:230–5.
37.\De Giacomi F, Decker PA, Vassallo R, Ryu JH. Acute eosinophilic pneumonia: correlation of clinical characteristics with underlying cause. Chest. 2017;152:379–85.
38.\Barroso E, Hernandez L, Gil J, Garcia R, Aranda I, Romero S. Idiopathic organizing pneumonia: a relapsing disease. 19 years of experience in a hospital setting. Respiration. 2007;74:624–31.
39.\Drakopanagiotakis F, Paschalaki K, Abu-Hijleh M, Aswad B, Karagianidis N, Kastanakis E, Braman SS, Polychronopoulos V. Cryptogenic and secondary organizing pneumonia: clinical presentation, radiographic ndings, treatment response and prognosis. Chest. 2011;139:893–900.
40.\Epler GR, Kelly EM. Post-breast cancer radiotherapy bronchiolitis obliterans organizing pneumonia. Respir Care. 2020;65:686–92.
41.\O’Driscoll BR, Kalra S, Gattamaneni HR, Woodcock AA. Late carmustine lung brosis. Age at treatment may infuence severity
and survival. Chest. 1995;107:1355–7. |
|
|
42.\Dixon DL, Dunn SP, Kelly MS, |
McLlarky TR, |
Brown |
RE. Effectiveness of pharmacist-led |
amiodarone |
monitor- |
ing services on improving adherence to amiodarone monitor- |
||
ing recommendations: a systematic review. Pharmacotherapy. |
||
2016;36:230–6. |
|
|
43.\Hotta T, Okimoto T, Hamaguchi M, Tsubata Y, Isobe T. Acute interstitial lung disease induced by rechallenge with ceritinib. Intern Med. 2020;59:253–6.
44.\Kwok WC, Ma TF, Chan JWM, Pang HH, Ho JCM. A multicenter retrospective cohort study on predicting the risk for amiodarone pulmonary toxicity. BMC Pulm Med. 2022;22:128–37.
45.\Chen X, Li Z, Wang X, Zhou J, Wei Q, Jiang R. Association of pre-existing lung interstitial changes with immune-related pneumonitis in patients with non-small lung cancer receiving immunotherapy. Support Care Cancer. 2022;30:6515.
46.\Bristedt P, Tylén U. Pulmonary edema following intravenous injection of nonionic low-osmolar contrast medium - appearance on HRCT - a case report. Acta Radiol. 1998;39:81–3.
47.\Picado C, Castillo JA, Montserrat JM, Agusti-Vidal A. Aspirin- intolerance as a precipitating factor of life-threatening attacks of asthma requiring mechanical ventilation. Eur Respir J. 1989;2:127–9.
48.\Bojanini L, Morgenstern-Kaplan D, Carrillo-Martin I, Vanegas YAM, Cuervo-Pardo L, Zwiener R, Gonzalez-Estrada A. Chemotherapy-induced anaphylaxis and fatal anaphylaxis in the United States: incidence and risk factors. Clin Exp Allergy. 2021;51:1514–8.
49.\Skolnik A, Monas J. The crashing toxicology patient. Emerg Med Clin North Am. 2020;38:841–56.
50.\Kiyatkin EA. Respiratory depression and brain hypoxia induced by opioid drugs: morphine, oxycodone, heroin, and fentanyl. Neuropharmacology. 2019;151:219–26.
772 |
P. Bonniaud and P. Camus |
|
|
51.\Vater LB, Lefebvre B, Turk A, Clasen SC. Fluoropyrimidine cardiotoxicity: incidence, outcomes, and safety of rechallenge. Curr Oncol Rep. 2022;24:943.
52.\Anderson RP, Zechar K. Lung injury from inhaling butane hash oil mimics pneumonia. Respir Med Case Rep. 2019;26:171–3.
53.\Bauer-Kemény C, Kreuter M. [Addictive inhalants - a challenge for the lungs]. Pneumologe (Berl). 2022;19:49–59.
54.\Okie S. A food of opioids, a rising tide of deaths. N Engl J Med. 2010;363:1981–5.
55.\Lineberry TW, Bostwick JM. Taking the physician out of “physician shopping”: a case series of clinical problems associated with Internet purchases of medication. Mayo Clin Proc. 2004;79:1031–4.
56.\Gilbert CR, Baram M, Cavarocchi NC. “Smoking wet”: respiratory failure related to smoking tainted marijuana cigarettes. Tex Heart Inst J. 2013;40:64–7.
57.\Lineberry TW, Bostwick JM. Methamphetamine abuse: a perfect storm of complications. Mayo Clin Proc. 2006;81:77–84.
58.\Koppen A, Wijnands-Kleukers APG, Gresnigt FMJ, de Lange DW. Clinical toxicology of exposures to chemicals from clandestine drug laboratories: a literature review. Clin Toxicol. 2022;60:559–70.
59.\Valverde-Monge M, Fernandez-Nieto M, Lopez VB, Rodrigo- Munoz JM, Canas JA, Sastre B, Garcia Del Potro M, De Las Heras M, Pozo VD, Sastre J. Novel causes of drug-induced occupational asthma. J Allergy Clin Immunol Pract. 2019;7:740–2.
60.\Leslie KO. My approach to interstitial lung disease using clinical, radiological and histopathological patterns. J Clin Pathol. 2009;62:387–401.
61.\Roden AC, Camus P. Iatrogenic pulmonary lesions. Semin Diagn Pathol. 2018;35:260–71.
62.\Moui A, Dirou S, Sagan C, Liberge R, Defrance C, Arrigoni PP, Morla O, Kandel-Aznar C, Cellerin L, Cavailles A, Eschapasse E, Morio F, Gourraud PA, Goronfot T, Tissot A, Blanc FX. Immune alveolitis in interstitial lung disease: an attractive cytological pro le in immunocompromised patients. BMC Pulm Med. 2022;22:79.
63.\Koo LC, Clark JA, Quesenberry CP, Higenbottam T, Nyberg F, Wolf MK, Steinberg MH, Forsythe BH. National differences in reporting ‘pneumonia’ and ‘pneumonia interstitial’: an analysis of the WHO International Drug Monitoring Database on 15 drugs in nine countries for seven pulmonary conditions. Pharmacoepidemiol Drug Saf. 2005;14:775–87.
64.\Dorr DA, Burdon R, West DP, Lagman J, Georgopoulos C, Belknap SM, McKoy JM, Djulbegovic B, Edwards BJ, Weitzman SA, Boyle S, Tallman MS, Talpaz M, Sartor O, Bennett CL. Quality of reporting of serious adverse drug events to an institutional review board: a case study with the novel cancer agent, imatinib mesylate. Clin Cancer Res. 2009;15:3850–5.
65.\Transport-Accident-Investigation-Commission. Aviation inquiry AO-2018-006 Robinson R44, ZK-HTB Loss of control Stevensons Arm, Lake Wanaka 21 July 2018 September 2020. Wellington: Transport; 2020. 52 p.
66.\Rodriguez-Reyes M, Marco-Hernandez J, Castro-Rebollo P, Soy- Muner D. Interstitial pneumonitis and myelosuppression associated to mitomycin C urinary tract instillations: a case report. J Oncol Pharm Pract. 2019;25:739–42.
67.\Matson SM, Demoruelle MK, Castro M. Airway disease in rheumatoid arthritis. Ann Am Thorac Soc. 2022;19:343–52.
68.\Montani D, Seferian A, Savale L, Simonneau G, Humbert M. Drug-induced pulmonary arterial hypertension: a recent outbreak. Eur Respir Rev. 2013;22:244–50.
69.\Savale L, Chaumais MC, Cottin V, Bergot E, Frachon I, Prevot G, Pison C, Dromer C, Poubeau P, Lamblin N, Habib G, Reynaud- Gaubert M, Bourdin A, Sanchez O, Tubert-Bitter P, Jais X,
Montani D, Sitbon O, Simonneau G, Humbert M. Pulmonary hypertension associated with benfuorex exposure. Eur Respir J. 2012;40:1164–72.
70.\Myers JL. Diagnosis of drug reactions in the lung. Monogr Pathol. 1993;36:32–53.
71.\Myers JL, Limper AH, Swensen SJ. Drug-induced lung disease: a pragmatic classi cation incorporating HRCT appearances. Semin Respir Crit Care Med. 2003;24:445–54.
72.\Camus P, Colby TV, Rosenow ECI. Amiodarone pulmonary toxicity. In: Camus P, Rosenow EC, editors. Drug-induced and iatrogenic lung disease. London: Hodder Arnold; 2010.
73.\Jennane S, Haidouri S, Zine Filali K, Ahchouch S, Mahtat E M, Doghmi K, Mikdame M. [Fatal bleomycin induced pneumomediastinum and bilateral pneumothorax]. Rev Pneumol Clin. 2017;73:153–6.
74.\Jansson PS, Leisten DC, Sarkisian TM, Wilcox SR, Lee J. Recurrent hydrochlorothiazide-induced acute respiratory distress syndrome treated with extracorporeal membrane oxygenation. J Emerg Med. 2018;55:836–40.
75.\Dinis-Oliveira RJ, Carvalho F, Duarte JA, Proenca JB, Santos A, Magalhaes T. Clinical and forensic signs related to cocaine abuse. Curr Drug Abuse Rev. 2012;5:64–83.
76.\Taskinen E, Tukainen P, Sovijärvi ARA. Nitrofurantoin-induced alterations in pulmonary tissue. A report on ve patients with acute or subacute reactions. Acta Pathol Microbiol Scand A. 1977;85:713–20.
77.\Milne EN, Pistolesi M, Miniati M, Giuntini C. The radiologic distinction of cardiogenic and noncardiogenic edema. AJR Am J Roentgenol. 1985;144:879–94.
78.\Maldonado M, Villamin CE, Murphy LE, Dasgupta A, Bassett RL, Correa Medina M, Bates TS, Martinez F, Knopfelmacher Couchonal AM, Klein K, Kelley JM. Oncology patients who develop transfusion-associated circulatory overload: an observational study. Lab Med. 2022;53:344.
79.\Megarbane B, Chevillard L. The large spectrum of pulmonary complications following illicit drug use: features and mechanisms. Chem Biol Interact. 2013;206:444–51.
80.\Jehn U, Göldel N, Rienmüller R, Wilmanns W. Non-cardiogenic pulmonary edema complicating intermediate and high-dose Ara C treatment for relapsed acute leukemia. Med Oncol Tumor Pharmacother. 1988;5:41–7.
81.\Glisson JK, Vesa TS, Bowling MR. Current management of salicylate-induced pulmonary edema. South Med J. 2011;104:225–32.
82.\Toy P, Looney MR, Popovsky M, Pal M, Berlin G, Chapman CE, Bolton-Maggs P, Matthay MA. Transfusion-related acute lung injury: 36 years of progress (1985-2021). Ann Am Thorac Soc. 2022;19:705.
83.\Lipshultz SE, Cochran TR, Franco VI, Miller TL. Treatment- related cardiotoxicity in survivors of childhood cancer. Nat Rev Clin Oncol. 2013;10:697–710.
84.\McCormick BJ, Kuhlman J, Chirila RM. 54-Year-old man with acute dyspnea on exertion. Mayo Clin Proc. 2022;97(5):1008–13.
85.\de Wall C, Bauersachs J, Berliner D. Cardiooncology-dealing with modern drug treatment, long-term complications, and cancer survivorship. Clin Exp Metastasis. 2021;38:361–71.
86.\Sridhar S, Kanne JP, Henry TS, Revels JW, Gotway MB, Ketai LH. Medication-induced pulmonary injury: a scenarioand pattern-based approach to a perplexing problem. Radiographics. 2022;42:38–55.
87.\Rivera MP, Detterbeck FC, Socinski MA, Moore DT, Edelman MJ, Jahan TM, Ansari RH, Luketich JD, Peng G, Monberg M, Obasaju CK, Gralla RJ. Impact of preoperative chemotherapy on pulmonary function tests in resectable early-stage non-small cell lung cancer. Chest. 2009;135:1588–95.
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
42 Drug-Induced/Iatrogenic Respiratory Disease: With Emphasis on Unusual, Rare, and Emergent Drug-Induced Reactions |
773 |
|
|
88.\Simpson AB, Paul J, Graham J, Kaye SB. Fatal bleomycin pulmonary toxicity in the west of Scotland 1991-95: a review of patients with germ cell tumours. Br J Cancer. 1998;78:1061–6.
89.\Warren K, Vu K, Shergill K, Watson B, Faris M. Rare complication of a commonly used antihypertensive agent: a case of hydralazine- induced ANCA-associated vasculitis presenting as rapidly progressive glomerulonephritis. Clin Case Rep. 2022;10:e05411.
90.\Kamijo Y, Sato C, Yoshimura K, Soma K. Notable pink excreta and severe myocardial suppression in superwarfarin (difethialone) intoxication. Intern Med. 2011;50:2819–22.
91.\Caravati EM, Erdman AR, Scharman EJ, Woolf AD, Chyka PA, Cobaugh DJ, Wax PM, Manoguerra AS, Christianson G, Nelson LS, Olson KR, Booze LL, Troutman WG. Long-acting anticoagulant rodenticide poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol. 2007;45:1–22.
92.\Schmid A, Tzur A, Leshko L, Krieger BP. Silicone embolism syndrome. A case report, review of the literature, and comparison with fat embolism syndrome. Chest. 2005;127:2276–81.
93.\Lewin-Smith M, Kalasinsky V, Shilo K, Tomashefski J, Cropp A. Detection of silicone in lung tissue. Arch Pathol Lab Med. 2012;136:1179–80.
94.\Choi HK, Slot MC, Pan GL, Weissbach CA, Niles JL, Merkel PA. Evaluation of antineutrophil cytoplasmic antibody seroconversion induced by minocycline, sulfasalazine, or penicillamine. Arthritis Rheum. 2000;43:2488–92.
95.\Choi HK, Merkel PA, Walker AM, Niles JL. Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: prevalence among patients with high titers of antimyeloperoxidase antibodies. Arthritis Rheum. 2000;43:405–13.
96.\Russe-Russe JR, Pellegrini JR Jr, Alvarez-Betancourt A, Munshi RF, Anand P. Fulminant anti-neutrophil cytoplasmic antibody- associated vasculitis after 10 years of hydralazine use. Cureus. 2021;13:e18974.
97.\Lazor R, Bigay-Game L, Cottin V, Cadranel J, Decaux O, Fellrath JM, Cordier JF. Alveolar hemorrhage in anti-basement membrane antibody disease: a series of 28 cases. Medicine (Baltimore). 2007;86:181–93.
98.\Murphy CE, Kenny CM, Brown KF. TACO and TRALI: visualising transfusion lung injury on plain lm. BMJ Case Rep. 2020;13:e230426.
99.\Van Ness M, Jensen H, Adamson GN, Kysar PE, Holland P. Neutrophils contain cholesterol crystals in Transfusion-Related Acute Lung Injury (TRALI). Am J Clin Pathol. 2013;140:170–6.
100.\Kopko PM, Marshall CS, MacKenzie MR, Holland PV, Popovsky MA. Transfusion-related acute lung injury. Report of a clinical look-back investigation. JAMA. 2002;287:1968–71.
101.\Vossoughi S, Gorlin J, Kessler DA, Hillyer CD, Van Buren NL, Jimenez A, Shaz BH. Ten years of TRALI mitigation: measuring our progress. Transfusion. 2019;59:2567.
102.\Tomari S, Homma K, Noguchi T, Aiba T, Matsuki T, Suzuki R, Koga M, Takigami M, Tagawa H, Hashimoto T, Toyoda K. Development of interstitial lung disease after initiation of apixaban anticoagulation therapy. J Stroke Cerebrovasc Dis. 2016;25:1767–9.
103.\Ghincea A, Ryu C, Herzog EL. An acute exacerbation of idiopathic pulmonary brosis after BNT162b2 mRNA COVID-19 vaccination: a case report. Chest. 2022;161:e71–3.
104.\Sgalla G, Magrì T, Lerede M, Comes A, Richeldi L. COVID-19 vaccine in patients with exacerbation of idiopathic pulmonarybrosis. Am J Respir Crit Care Med. 2022;206:219.
105.\Fuhrman C, Parrot A, Wislez M, Prigent H, Boussaud V, Bernaudin JF, Mayaud C, Cadranel J. Spectrum of CD4 to CD8 T-cell ratios in lymphocytic alveolitis associated with methotrexate-induced pneumonitis. Am J Respir Crit Care Med. 2001;164:1186–91.
106.\Blackwell TS, Gossage JR. Gold pulmonary toxicity in a patient with a normal chest radiograph. South Med J. 1995;88:644–6.
107.\Ashida C, Kinoshita K, Nozaki Y, Funauchi M. Fatal outcome in a patient under immunosuppressant therapy infected with human T-lymphotropic virus type 1 (HTLV-1), cytomegalovirus (CMV) and Strongyloides stercoralis: a case report. BMC Infect Dis. 2020;20:470.
108.\Tazelaar HD, Linz LJ, Colby TV, Myers JL, Limper AH. Acute eosinophilic pneumonia: histopathologic ndings in nine patients. Am J Respir Crit Care Med. 1997;155:296–302.
109.\Nasim F, Paul JA, Boland-Froemming J, Wylam ME. Sulfa- induced acute eosinophilic pneumonia. Respir Med Case Rep. 2021;34:101496.
110.\Hauser T, Mahr A, Metzler C, Coste J, Sommerstein R, Gross WL, Guillevin L, Hellmich B. The leucotriene receptor antagonist montelukast and the risk of Churg-Strauss syndrome: a case- crossover study. Thorax. 2008;63:677–82.
111.\Bibby S, Healy B, Steele R, Kumareswaran K, Nelson H, Beasley R. Association between leukotriene receptor antagonist therapy and Churg-Strauss syndrome: an analysis of the FDA AERS database. Thorax. 2010;65:132–8.
112.\Miedema J, Nunes H. Drug-induced sarcoidosis-like reactions. Curr Opin Pulm Med. 2021;27:439–47.
113.\Mukhopadhyay S. Role of histology in the diagnosis of infectious causes of granulomatous lung disease. Curr Opin Pulm Med. 2011;17:189–96.
114.\Aydogan Eroglu S, Yildiz T, Sonkaya E, Kavas M, Ozbaki F, Sertçelik L, Sen A, Sevim T. Diagnosis distribution in cases with granulomatous infammation in lung, pleura, and lymph node biopsies: an experience from a tertiary level single center chest diseases and thoracic surgery hospital. Sarcoidosis Vasc Diffuse Lung Dis. 2022;38:e2021048.
115.\Mukhopadhyay S, Wilcox BE, Myers JL, Bryant SC, Buckwalter SP, Wengenack NL, Yi ES, Aughenbaugh GL, Specks U, Aubry MC. Pulmonary necrotizing granulomas of unknown cause: clinical and pathologic analysis of 131 patients with completely resected nodules. Chest. 2013;144:813–24.
116.\Imokawa S, Colby TV, Leslie KO, Helmers RA. Methotrexate pneumonitis: review of the literature and histopathological ndings in nine patients. Eur Respir J. 2000;15:373–81.
117.\Cottin V, Bendstrup E, Bonniaud P, Nasser M, Spagnolo P, Valenzuela C, Kolb M. The case of methotrexate and the lung: Dr Jekyll and Mr Hyde. Eur Respir J. 2021;57:2100079.
118.\Kremer JM, Alarcon GS, Weinblatt ME, Kaymakcian MV, Macaluso M, Cannon GW, Palmer WR, Sundy JS, St Clair EW, Alexander RW, Walker-Smith GJ, Axiotis CA. Clinical, laboratory, radiographic, and histopathologic features of methotrexate- associated lung injury in patients with rheumatoid arthritis. Arthritis Rheum. 1997;40:1829–37.
119.\Notghi AAA, Hosseini F, Tsogas N. Severe diffuse proliferative bronchiolitis complicating culture-proven disseminated BCG infection after intravesical instillation for bladder cancer. BMJ Case Rep. 2022;15:e248681.
120.\Hofand RW, Thijsen SF, Verhagen MA, Schenk Y, Bossink AW. Tuberculosis during TNF-alpha inhibitor therapy, despite screening. Thorax. 2013;68:1079–80.
121.\Hossein-Zadeh Z, Shuman MJ, Rapkiewicz A. Fatal excipients: an autopsy case series of excipient lung disease. Am J Forensic Med Pathol. 2022;43:81–9.
122.\Westphalen SS, Torres FS, Tonetto MS, Zampieri JF, Torri GB, Garcia TS. Interobserver agreement regarding the Fleischner Society diagnostic criteria for usual interstitial pneumonia patterns on computed tomography. Radiol Bras. 2022;55:71–7.
123.\Conte P,Ascierto PA, Patelli G, Danesi R,VanzulliA, Sandomenico F, Tarsia P, Cattelan A, Comes A, De Laurentiis M, Falcone A, Regge D, Richeldi L, Siena S. Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment. ESMO Open. 2022;7:100404.
774 |
P. Bonniaud and P. Camus |
|
|
124.\Beasley MB, Franks TJ, Galvin JR, Gochuico |
B, Travis |
WD. Acute brinous and organizing pneumonia. A histologic pat- |
|
tern of lung injury and possible variant of diffuse alveolar damage. |
|
Arch Pathol Lab Med. 2002;126:1064–70. |
|
125.\Karnatovskaia LV, Festic E, Gajic O, Carter |
RE, Lee |
AS. Prehospital amiodarone may increase the incidence of acute respiratory distress syndrome among patients at risk. J Crit Care. 2012;27:447–53.
126.\van Mieghem W, Coolen L, Malysse I, Lacquet LM, Deneffe GJD, Demedts MGP. Amiodarone and the development of ARDS after lung surgery. Chest. 1994;105:1642–5.
127.\Saussine M, Colson P, Alauzen M, Mary H. Postoperative acute respiratory distress syndrome. A complication of amiodarone associated with 100 percent oxygen ventilation. Chest. 1992;102:980–1.
128.\Larsen BT, Vaszar LT, Colby TV, Tazelaar HD. Lymphoid hyperplasia and eosinophilic pneumonia as histologic manifestations of amiodarone-induced lung toxicity. Am J Surg Pathol. 2012;36:509–16.
129.\Affeck A, Goudie A, Smith R. Fatal, incidental, idiopathic pulmonary brosis in a patient receiving long-term low-dose methotrexate for psoriasis. Clin Exp Dermatol. 2019;44:591–2.
130.\Al Nokhatha SA, Harrington R, Conway R. Is methotrexate contra-indicated in lung involvement of rheumatoid arthritis? Joint Bone Spine. 2020;87:535–7.
131.\Juge PA, Lee JS, Lau J, Kawano-Dourado L, Rojas Serrano J, Sebastiani M, Koduri G, Matteson E, Bon glioli K, Sawamura M, Kairalla R, Cavagna L, Bozzalla Cassione E, Manfredi A, Mejia M, Rodríguez-Henriquez P, González-Pérez MI, Falfán-Valencia R, Buendia-Roldán I, Pérez-Rubio G, et al. Methotrexate and rheumatoid arthritis associated interstitial lung disease. Eur Respir J. 2021;57:2000337.
132.\Certain MC, Georges M, Beltramo G, Schenesse D, Mouillot P, Tankéré P, Bonniaud P. Adalimumab-induced interstitial pneumonia in patients with infammatory bowel disease. Respir Med Res. 2020;78:100790.
133.\Schuller A, Coudurier M, Lega JC, Khouatra C, Cottin V, Cordier JF. Interstitial lung disease and anti-TNF-alpha therapy in rheumatoid arthritis: two different patterns? Rev Mal Respir. 2010;27:232–7.
134.\Wolfe F, Caplan L, Michaud K. Rheumatoid arthritis treatment and the risk of severe interstitial lung disease. Scand J Rheumatol. 2007;36:172–8.
135.\Hagiwara K, Sato T, Takagi Kobayashi S, Hasegawa S, Shigihara N, Akiyama O. Acute exacerbation of preexisting interstitial lung disease after administration of etanercept for rheumatoid arthritis. J Rheumatol. 2007;34:1151–4.
136.\Dixon WG, Hyrich KL, Watson KD, Lunt M, Symmons DP. Infuence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2010;69:1086–91.
137.\Cohen JV, Capell BC, Kinniry PA, Epstein AL. Rapidly fatal pulmonary brosis in a patient with psoriatic arthritis treated with adalimumab. J Rheumatol. 2011;38:398–9.
138.\Curtis JR, Sarsour K, Napalkov P, Costa LA, Schulman KL. Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor alpha agents, a retrospective cohort study. Arthritis Res Ther. 2015;17:319.
139.\Parambil JG, Myers JL, Aubry MC, Ryu JH. Causes and prognosis of diffuse alveolar damage diagnosed on surgical lung biopsy. Chest. 2007;132:50–7.
140.\Saravanan V, Kelly CA. Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis. Rheumatology (Oxford). 2004;43:143–7.
141.\Dawson JK, Quah E, Earnshaw B, Amoasii C, Mudawi T, Spencer LG. Does methotrexate cause progressive brotic interstitial lung disease? A systematic review. Rheumatol Int. 2021;41:1055–64.
142.\Ueno T, Ohta T, Sugio Y, Ohno Y, Uehara Y. Severe acute interstitial lung disease after BNT162b2 mRNA COVID-19 vaccination in a patient post HLA-haploidentical hematopoietic stem cell transplantation. Bone Marrow Transplant. 2022;57:1–3.
143.\The-International-Collaborative-Study-of-Severe-Anaphylaxis. Risk of anaphylaxis in a hospital population in relation to the use of various drugs: an international study. Pharmacoepidemiol Drug Saf. 2003;12:195–202.
144.\Hyeon CW, Lee JY, Jang S, Cho SI, Kim S, Lee W, Shin S. Medical malpractice related to drug-induced anaphylaxis: an analysis of lawsuit judgments in South Korea. Medicine (Baltimore). 2019;98:e15996.
145.\Lieberman PL. Recognition and rst-line treatment of anaphylaxis. Am J Med. 2014;127:S6–11.
146.\Pumphrey RSH. Lessons from management of anaphylaxis from a study of fatal reactions. Clin Exp Allergy. 2000;30:1144–50.
147.\Pumphrey RS, Stanworth SJ. The clinical spectrum of anaphylaxis in north-west England. Clin Exp Allergy. 1996;26:1364–70.
148.\Muraro A, Worm M, Alviani C, Cardona V, DunnGalvin A, Garvey LH, Riggioni C, de Silva D, Angier E, Arasi S, Bellou A, Beyer K, Bijlhout D, Bilò MB, Bindslev-Jensen C, Brockow K, Fernandez-Rivas M, Halken S, Jensen B, Khaleva E, et al. EAACI guidelines: anaphylaxis (2021 update). Allergy. 2022;77:357–77.
149.\Barni S, Mori F, Giovannini M, de Luca M, Novembre E. In situ simulation in the management of anaphylaxis in a pediatric emergency department. Intern Emerg Med. 2019;14:127–32.
150.\Ulusoy OL, Kahraman S, Karalok I, Kaya E, Enercan M, Sever C, Abay B, Karadereler S, Hamzaoglu A. Pulmonary cement embolism following cement-augmented fenestrated pedicle screw xation in adult spinal deformity patients with severe osteoporosis (analysis of 2978 fenestrated screws). Eur Spine J. 2018;27:2348–56.
151.\Oshinsky C, Bhavani S, Funaki A. Cement cardiac embolism following kyphoplasty noted on thoracic imaging. Radiol Case Rep. 2018;13:914–6.
152.\Jouneau S, Vauléon E, Caulet-Maugendre S, Polard E, Volatron A-C, Meunier C, Tattevin P, Montani D, Garin E, Raoul J-L, Delaval P. 131I-labeled lipiodol-induced interstitial pneumonia: a series of 15 cases. Chest. 2010;139:1463–9.
153.\Esposito M, Montana A, Liberto A, Filetti V, Nunno ND, Amico F, Salerno M, Loreto C, Sessa F. Anaphylactic death: a new forensic workfow for diagnosis. Healthcare. 2021;9:117–32.
154.\Weisman DS, Arnouk N, Asghar MB, Qureshi MR, Kumar A, Desale S, Camire L, Pineda S. ACE inhibitor angioedema: characterization and treatment versus non-ACE angioedema in acute hospitalized patients. J Commun Hosp Intern Med Perspect. 2020;10:16–8.
155.\Wilkerson RG, Winters ME. Angiotensin-converting enzyme inhibitor-induced angioedema. Emerg Med Clin North Am. 2022;40:79–98.
156.\Jackeviciute J, Pilvinis V, Pilviniene R. Fatal outcome of late-onset angiotensin-converting enzyme inhibitor induced angioedema: a case report. Medicine (Baltimore). 2018;97:e11695.
157.\Rasmussen ER, Bygum A. ACE-inhibitor induced angio-oedema treated with complement C1-inhibitor concentrate. BMJ Case Rep. 2013;2013:bcr2013200652.
158.\Depetri F, Tedeschi A, Cugno M. Angioedema and emergency medicine: from pathophysiology to diagnosis and treatment. Eur J Intern Med. 2019;59:8–13.
159.\Brown NJ, Snowden M, Grif n MR. Recurrent angiotensin- converting enzyme inhibitor-associated angioedema. JAMA. 1997;278:232–3.
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
42 Drug-Induced/Iatrogenic Respiratory Disease: With Emphasis on Unusual, Rare, and Emergent Drug-Induced Reactions |
775 |
|
|
160.\Foucher P, Merati M, Baudouin N, Reybet-Degat O, Camus P, Jeannin L. Fatal ball-valve airway obstruction by an extensive blood clot during mechanical ventilation. Eur Respir J. 1996;9:2181–2.
161.\Sethia R, Bishop R, Gordian-Arroyo A, Matrka L. Iron pill- induced chemical laryngitis. Ann Otol Rhinol Laryngol. 2022;34894221075115
162.\Lee P, Culver DA, Farver C, Mehta AC. Syndrome of iron pill aspiration. Chest. 2002;121:1355–7.
163.\Küpeli E, Khemasuwan D, Lee P, Mehta AC. “Pills” and the air passages. Chest. 2013;144:651–60.
164.\Kupeli E, Khemasuwan D, Tunsupon P, Mehta AC. “Pills” and the air passages: a continuum. Chest. 2015;147:242–50.
165.\Picado C. Classi cation of severe asthma exacerbations: a proposal. Eur Respir J. 1996;9:1775–8.
166.\Fallow eld JM, Marlow HF. Propranolol is contraindicated in asthma. Br Med J. 1996;313:1486.
167.\Spitz DJ. An unusual death in an asthmatic patient. Am J Forensic Med Pathol. 2003;24:271–2.
168.\Ridley-Smith RM. A fatal error. N Z Med J. 2007;120:U2570. 169.\Bennett M, Chang CL, Tatley M, Savage R, Hancox RJ. The
safety of cardioselective β(1)-blockers in asthma: literature review and search of global pharmacovigilance safety reports. ERJ Open Res. 2021;7:00801–2020.
170.\Levine M, Iliescu ME, Margellos-Anast H, Estarziau M, Ansell DA. The effects of cocaine and heroin use on intubation rates and hospital utilization in patients with acute asthma exacerbations. Chest. 2005;128:1951–7.
171.\Krantz AJ, Hershow RC, Prachand N, Hayden DM, Franklin C, Hryhorczuk DO. Heroin insuffation as a trigger for patients with life-threatening asthma. Chest. 2003;123:510–7.
172.\Grant-Al eri A, Schaechter J, Lipshultz SE. Ingesting and aspirating dry cinnamon by children and adolescents: the “cinnamon challenge”. Pediatrics. 2013;131:833–5.
173.\Barbara DW, Ronan KP, Maddox DE, Warner MA. Perioperative angioedema: background, diagnosis, and management. J Clin Anesth. 2013;25:335.
174.\Percy MJ, McFerran NV, Lappin TR. Disorders of oxidised haemoglobin. Blood Rev. 2005;19:61–8.
175.\Lefevre T, Nuzzo A, Megarbane B. Poppers-induced life- threatening methemoglobinemia. Am J Respir Crit Care Med. 2018;198:e137–8.
176.\Brown C, Bowling M. Methemoglobinemia in bronchoscopy: a case series and a review of the literature. J Bronchol Interv Pulmonol. 2013;20:241–6.
177.\IngrassiaTSI,RyuJH,TrastekVF,RosenowECI.Oxygen-exacerbated bleomycin pulmonary toxicity. Mayo Clin Proc. 1991;66:173–8.
178.\Connolly S, Hountras P. A 49-Year-old woman with chest pain, cough, and hypoxemia after a seizure. Chest. 2019;155:e113–6.
179.\West JB. Fragility of pulmonary capillaries. J Appl Physiol. 2013;115:1–15.
180.\Willms D, Shure D. Pulmonary edema due to upper airway obstruction in adults. Chest. 1988;94:1090–2.
181.\Gondouin A, Manzoni P, Ranfaing E, Brun J, Cadranel J, Sadoun D, Cordier JF, Depierre A, Dalphin JC. Exogenous lipid pneumonia: a retrospective multicentre study of 44 cases in France. Eur Respir J. 1996;9:1463–9.
182.\Chouri N, Langin T, Lantuejoul S, Coulomb M, Brambilla C. Pulmonary nodules with the CT halo sign. Respiration. 2002;69:103–6.
183.\Ruangchira-Urai R, Colby TV, Klein J, Nielsen GP, Kradin RL, Mark EJ. Nodular amiodarone lung disease. Am J Surg Pathol. 2008;32:1654–60.
184.\von der Thüsen JH, Hansell DM, Tominaga M, Veys PA, Ashworth MT, Owens CM, Nicholson AG. Pleuroparenchymal broelastosis in patients with pulmonary disease secondary to bone marrow transplantation. Mod Pathol. 2011;24:1633–9.
185.\von der Thüsen JH. Pleuroparenchymal broelastosis: its pathological characteristics. Curr Respir Med Rev. 2013;9:238–47.
186.\Camus P, von der Thusen J, Hansell DM, Colby TV. Pleuroparenchymal broelastosis: one more walk on the wild side of drugs? Eur Respir J. 2014;44:289–96.
187.\Rodrigues Vieira AC, Monteiro Ferra JR, Vicente De Carvalho JS, Melo N, Caetano Mota P, Novais EBH, Pereira JM, Souto Moura C, Morais A. Pleuroparenchymal broelastosis as a complication of chemotherapy: a case report. Mol. Clin Oncol. 2022;16:71.
188.\Beynat-Mouterde C, Beltramo G, Lezmi G, Pernet D, Camus C, Fanton A, Foucher P, Cottin V, Bonniaud P. Pleuroparenchymalbroelastosis as a late complication of chemotherapy agents. Eur Respir J. 2014;44:523–7.
189.\Ni Chroinin D, Gaine S. Cracking the case: a patient with persistent delirium due to body packing with cocaine. Ir Med J. 2012;105:118–9.
190.\Manzella A, Filho PB, Albuquerque E, Farias F, Kaercher J. Imaging of gossypibomas: pictorial review. AJR Am J Roentgenol. 2009;193:S94–101.
191.\Nemati MH. Mediastinal gossypiboma simulating a malignant tumour. Interact Cardiovasc Thorac Surg. 2012;15:783–5.
192.\Yilmaz Durmaz D, Yilmaz BK, Yildiz O, Bas Y. A rare cause of chronic cough: intrathoracic gossypiboma. Iran J Radiol. 2014;11:e13933.